Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review

Feiying Guo; Huajie Zhong; Yuan Wu; Xue Xu; Jiarong Tan; Qiang Zhou; Shunli Tang

doi:10.3389/fmed.2025.1485079

Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review

Front Med (Lausanne). 2025 Feb 5:12:1485079. doi: 10.3389/fmed.2025.1485079. eCollection 2025.

Authors

Feiying Guo^#^{1

2

3}, Huajie Zhong^#^{1

2}, Yuan Wu^{1

2}, Xue Xu^{1

2}, Jiarong Tan⁴, Qiang Zhou³, Shunli Tang^{1

2}

Affiliations

¹ Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, China.
² Department of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.
³ Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁴ Department of Otolaryngology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.

^# Contributed equally.

Abstract

Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.

Keywords: amyloidosis; amyloidosis–therapy; case report; dupliumab; review.

Publication types

Case Reports